Venavine Intensive® in the Treatment of Symptoms Associated With Chronic Venous Insufficiency

Venous Insufficiency Clinical Trial

Official title:

The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 in the Treatment of Symptoms Associated With Chronic Venous Insufficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02483962
• Other study ID #: FayroozKarriem200800851
• Status: Completed
• Phase: Phase 2
• First received: June 25, 2015
• Last updated: May 18, 2016
• Start date: February 2015
• Est. completion date: August 2015

Study information

• Verified date: May 2016
• Source: University of Johannesburg
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Africa: National Health Research Ethics Council
• Study type: Interventional

Clinical Trial Summary

Chronic Venous Insufficiency (CVI) occurs when the veins in the lower limbs can no longer sufficiently pump enough blood back to the heart. Symptoms may include: dull aching, cramping, itching or tingling in the calves, swelling, redness or any colour changes as well as thickening of the skin in the lower limbs. The most common indication of CVI is dilated veins known as varicose veins. CVI is a disorder found more commonly in females. Conventional treatments for CVI include vein ligation or stripping, elastic compression, valve reconstruction and sclerotherapy venous bypass. Amongst other treatment, exercise has also proven to be effective in improving CVI as it increases circulation, by increasing blood returning to the heart. A variety of herbal supplements have been proven to be safe and effective in the treatment of CVI. Red vine leaf extract has also been proven to be useful in the treatment of CVI. Previous studies on the red vine leaf extract have shown that it is an effective and safe treatment of CVI. Studies done on horse chestnut extract have stated that the extract increases venous tone and decreases capillary permeability. Butcher's broom extract has been proven to be effective in the treatment of CVI. There are currently no studies done on the combination of red vine leaf extract, butcher's broom extract, horse chestnut extract and vitamin B6.

The aim of this study is to determine the efficacy of a combination of red vine leaf extract (360mg), horse chestnut extract (60mg), butcher's broom extract (35mg) and pyridoxine (vitamin B6) (3.2mg) in the treatment of symptoms associated with CVI, using a Venous Clinical Severity Score questionnaire (VCSS) .

Description:

This study is a 90 day, match paired, double-blinded, placebo-controlled study involving forty females participants between the ages of 30 and 55. Participants will be recruited via advertisements placed at the University of Johannesburg (UJ) Health Centre and on the campus. This sample group will be shared with another Homoeopathy Masters student, Xoliswa Mazibuko, who will be evaluating the changes in the quality of life using combination of red vine leaf extract, butcher's broom, horse chestnut extract and vitamin B6.

All consultations will take place at the UJ Health Centre, Doornfontein campus. The initial consultation will consist of signing of the Participant Information and Consent form as well as a Photograph Consent Form, followed by a screening test to confirm if participants qualify to participate in the study. All symptoms will be evaluated according to the Venous Clinical Severity Score (VCSS) questionnaire. Photographs of physical symptoms will also be taken, with the consent of the participant, in the initial consultation. Participants will be matched according to their age and severity of their symptoms. The bottles containing the placebo capsules will be placed in one box and the bottles containing the experimental capsules will be placed in another box. The boxes will be labelled X and Y. Each bottle will contain either 30 placebo capsules or 30 experimental capsules, as per their box group. The participants will then select a bottle from one of the boxes , thereby allocating themselves to either the experimental group or the control group. The participants will be requested to ingest one capsule from their selected bottle, every morning after breakfast for 30 consecutive days.

Follow up consultations will take place on days thirty, sixty and ninety. At each follow up consultation, the participants will be asked to complete the VCSS questionnaire, with the help of the researcher, and photographs of the same anatomical landmarks as taken in the initial consultation, will be taken. All photographs will be analysed by the Digimizer programme, which will calculate any changes in surface area from week one to week twelve. Photographs will be taken in such a way that the dignity and privacy of the participant is maintained.

Participants will be given medication for the next thirty days at each follow-up consultation excluding the final consultation (day 90).

If any other treatment or intervention is used during the duration of the study, they will be requested to notify the researcher.

Data will be collected from the questionnaire and analysed statistically with the assistance of a statistician at Statkon. Differences between the Inter-group will be analysed using the Friedman test with Wilcoxon post hoc test. To compare the different sets of data between the Intra-group, the Mann-Whitney test will be used. All photographs will be analysed by Digimizer programme.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years to 55 Years

Eligibility

Inclusion Criteria:

• Females;

• aged 30 to 55 years;

• experiences at least three symptoms from Clinical, Etiologic, Anatomic, and Pathophysiologic (CEAP) C1-C4 of CVI which include varicose veins, tired or heavy legs, pain in the legs, tingling calves, venous oedema, induration of the legs, brown discolouration in the legs, skin changes such as erythema in the legs; and

• symptoms must be aggravated by walking/standing and symptoms are ameliorated by rest and limb elevation.

Exclusion Criteria:

• Pregnant or lactating females;

• taking chronic medication for cardiovascular disorder;

• have any chronic diseases that are not sufficiently managed;

• experiencing symptoms from CEAP C5-C6 of CVI, which includes venous ulceration;

• have a previous history of deep vein thrombosis;

• are on Warfarin or blood thinning medication;

• have any liver or kidney pathologies;

• are hypersensitive to any/all herbal extracts;

• are on any treatment (herbal or conventional) for CVI; and/or

• use compression stockings or Kinesio Taping therapy.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Venous Insufficiency

Intervention

Other:
• Gelatine capsule
Gelatine capsules containing no active ingredients.
• Venavine Intensive®
Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.

Locations

Country	Name	City	State
South Africa	University of Johannesburg	Johannesburg	Gauteng

Sponsors (1)

Lead Sponsor	Collaborator
University of Johannesburg

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severity of chronic venous insufficiency symptoms as measured by the Venous Clinical Severity Score (VCSS)	The VCSS is an effective tool in grading the severity of the symptoms of chronic venous insufficiency in response to treatment.	Every 30 days in a period of 90 days	No
Secondary	Changes in surface area of the affected skin of the lower limbs as measured by photographs analysed by the Digimizer programme	The Digimizer programme calculates any changes in the surface area of the skin.	Every 30 days in a period of 90 days	No